Cempra (CEMP): Approval Vote Adds Burdensome Marketing Restrictions - Baird

November 7, 2016 7:20 AM EST
Get Alerts CEMP Hot Sheet
Price: $3.25 --0%

Rating Summary:
    2 Buy, 12 Hold, 2 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 13 | Down: 22 | New: 54
Trade CEMP Now!
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Baird analyst, Brian Skorney, reiterated his Underperform rating on shares of Cempra, Inc. (NASDAQ: CEMP) aafter the mixed panel vote on Soli.

The vote was 7-6 in favor of approval but marketing restrictions are likely to be so burdensome that based on panelists concerns over drug-induced liver injury and the unanimous requests to restrict and monitor it, the commercial potential could be negligible.

Although the analyst expects the stock to give up some of its losses on short covering, he continues to see the soli opportunity as fundamentally impaired by safety concerns.

No change to the price target of $6.

For an analyst ratings summary and ratings history on Cempra, Inc. click here. For more ratings news on Cempra, Inc. click here.

Shares of Cempra, Inc. closed at $7.55 yesterday.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS View, FDA

Related Entities

Robert W Baird

Add Your Comment